National Institute of Allergy and Infectious Diseases

The National Institute of Allergy and Infectious Diseases (NIAID) is an American government agency underneath the National Institutes of Health, which itself operates under the United States Department of Health and Human Services (HHS).


Intellectual property

NIAID holds patent rights to a modified version of the SARS-CoV-2 spike protein, which have been licensed for use in currently available COVID-19 vaccines including mRNA-1273 and BNT162b2.1) The associated patents are:2) 3)

The inventors listed on these patents within NIAID are financial beneficiaries of their use, presenting a conflict of interest between NIAID and pharmaceutical companies including Moderna and Pfizer.4)

In May 2022, NIAID licensed various COVID-19-related technologies to the World Health Organization's COVID-19 Technology Access Pool (C-TAP).5) 6)

Rizvi, Z. (2020, June 25). The NIH Vaccine. Public Citizen.
Petrik, A. (2022, April 28). Prefusion Coronavirus Spike Proteins and Their Use. NIH Technology Transfer.
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367(6483), 1260–1263.
COVID-19 Vaccines: Dr. Fauci’s Team May Personally Profit. (2020, October 11). ICAN - Informed Consent Action Network.
NIH Contributions to WHO COVID-19 Technology Access Pool and Q&As | Technology Transfer. (2022, May 12). National Institutes of Health.
US NIH licenses to C-TAP. World Health Organization. Retrieved March 1, 2023, from
Back to top